GLP-1 receptor agonists have not been shown to adversely affect liver function
Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes
No personalized formulations like adding B12 or other supportive ingredients
Microdose tirzepatide uses a lower-dose version of that dual-pathway strategy
Neuroglycopenic symptoms result from inadequate glucose supply to the central nervous system and can range from mild manifestations, such as blurred vision, lightheadedness, flushing, lethargy, and weakness, to more severe consequences, including seizures, unconsciousness, disorientation, and speech difficulties [44]